ONVO Organovo Corp: Rasio rega marang prakiraan pendapatan

Organovo Holdings, Inc. - logo grafis emiten ONVO

Organovo Holdings, Inc. (ONVO) is implementing an ethical approach by replacing animal testing with 3D bioprinting of tissues. The forward P/S ratio helps assess the asset's attractiveness, while the value of 28.70 reflects the metric's balance. The company relies on its unique NovoGen technology to create liver structures in high demand among pharma behemoths. The stability of R&D processes is ensured by regular updates to bioprinters to achieve maximum cell positioning precision.

Organovo - Rasio kapitalisasi marang dodolan sing dikarepake ONVO (periode 04.07.2022 - 24.04.2025)

Ringkesan rincian data analitis organovo.com (ONVO)

- rega pasar lan target rega analis:
Analisis wiwitan perusahaan:ONVO (Organovo Holdings Inc)
Produk asli Organovo Holdings, Inc.

This indicator assesses market capitalization relative to expected sales volume, allowing investors to determine the degree of asset overvaluation based on forward-looking data. By analyzing the forward price-to-sales ratio, one can see how the lack of current revenues at Organovo Holdings, Inc. (ONVO) and the R&D costs of 3D bioprinting create speculative pressure, turning the metric into a tool for monitoring capital dilution risks.

Pesaing wigati

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan newamsterdampharma.com (NAMS)|Multiplikator forward rega marang pendapatan soleno.life SLNO|Multiplikator Forward P/S FOLD (amicusrx.com)|Rasio kapitalisasi marang dodolan sing dikarepake 89bio (ETNB)|Agios - Multiplikator Forward P/S|Structure Corp - Rasio rega marang pendapatan sing dikarepake|mimedx.com (MDXG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan MBX|Rasio rega marang prakiraan pendapatan Altimmune Pharma (ALT)|Rasio rega marang prakiraan pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator Forward P/S SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BMEA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Multiplikator forward rega marang pendapatan|vTv Therapeutics, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Agape ATP Corp.|Multiplikator forward rega marang pendapatan Pluri (PLUR)|Multiplikator Forward P/S SYBX|Rasio kapitalisasi marang dodolan sing dikarepake Lipocine Inc|Rasio rega marang prakiraan pendapatan Matinas BioPharma Holdings MTNB|Rasio kapitalisasi marang dodolan sing dikarepake Spruce Biosciences (SPRB)|GLTO: Multiplikator forward rega marang pendapatan|Rega mangsa ngarep marang pendapatan CTCX|LUMO (Lumos Pharma) - Multiplikator forward rega marang pendapatan|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan